Please ensure Javascript is enabled for purposes of website accessibility

Biotech Company Loyal Appoints Blake Scholl to Board of Directors

Glenn Polyn//February 15, 2023//

Biotech Company Loyal Appoints Blake Scholl to Board of Directors

Glenn Polyn //February 15, 2023//

Listen to this article

Press release: Loyal

Loyal, a biotech company developing the world’s first  drugs intended to extend the healthy lifespan of dogs, announced today that Blake Scholl has joined as an independent director. Scholl brings over 20 years of successful startup, technical and commercial experience to Loyal as the company progresses towards FDA approval and bringing their first dog aging drugs to vets and pet parents.

Blake Scholl is the Founder and CEO of Boom Supersonic, the company building the world’s fastest airliner. Boom has built XB-1, history’s first independently-developed supersonic jet, and taken orders and pre-orders for Overture, its supersonic passenger airliner. Prior to founding Boom in 2014, Blake held leadership roles at Amazon and Groupon and co-founded mobile technology startup Kima Labs.

Blake joins existing board of directors Laura Deming of The Longevity Fund and Celine Halioua, and board observers Josh Kopelman of First Round Capital and Greg Rosen of Box Group.

“I’m extremely excited that Blake is joining Loyal’s Board. Blake is fascinated with longevity science, has a strong passion for tackling big, important problems, and has invaluable experience bringing entirely new products to consumers,” stated Loyal CEO and founder Celine Halioua. “I look forward to learning from and working with Blake.”

“Time is one of the most valuable commodities we have, which is why I’m inspired by Loyal’s mission to extend the time we have with our best friends, and increase their healthspan,” said Blake Scholl. “I’m excited to contribute my experience to their efforts.”

Scholl’s appointment comes after key company milestones in the last year, including administering the first aging drug to a companion dog– Josie, a seven-year-old Mastiff– and successfully completing canine efficacy studies for both of their drug programs: LOY001, intended for lifespan extension for large dogs, and LOY002, intended for lifespan extension for old dogs of any size. Loyal also recently concluded its X-Thousand Dogs Study, the largest dog epigenetics study in history, one of many efforts to quantify the processes of pathological versus healthy aging.